Bobby Shah, MD
Pulmonary Disease · Chesterfield, MONPI 1538340930
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $199,563 of the $241,011 with a category attached, or 82.8%. GSK accounts for 67.0% of it on its own, with 53 other manufacturers making up the rest. Among pulmonary disease clinicians in MO with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,216 payments — averaging $198.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$161K
- Sanofi$30K
- Mylan Specialty L.p.$24K
- Boehringer Ingelheim$13K
- AstraZeneca$2K
- Verona Pharma, Inc.$2K
- plus $9K from 48 others
Across 6 payments — averaging $2535.25 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- GSK$15K
What the payments were for
- Consulting fees$5,6002%
- Speaking & faculty fees$199,56383%
- Travel & lodging$14,9796%
- Food & beverage$20,5519%
- Education$3190%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TRELEGY ELLIPTA$81,341
- NUCALA$40,416
- DUPIXENT$33,354
- Yupelri$23,338
- ANORO$12,820
- Ohtuvayre$1,500
- ANORO ELLIPTA$1,200
- AIRSUPRA$409
- TEZSPIRE$304
- BREZTRI$287
- IMFINZI$182
- FASENRA$182
- ILLUMISITE$141
- GIAPREZA$116
- SYMBICORT$105
How this compares
$241,011 in reported general payments places this provider in the 95th percentile of 295 pulmonary disease providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 901 | $787,751 |
| OfevNintedanib Esylate | 52 | $697,961 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 616 | $365,012 |
| Breo ElliptaFluticasone/Vilanterol | 397 | $201,551 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 106 | $108,635 |
| EliquisApixaban | 82 | $96,894 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 102 | $73,041 |
| Dupixent PenDupilumab | 17 | $62,437 |
| XareltoRivaroxaban | 53 | $57,336 |
| NucalaMepolizumab | 13 | $54,580 |
| AdcircaTadalafil | 11 | $45,870 |
| SymbicortBudesonide/Formoterol Fumarate | 119 | $38,520 |
| Ambrisentan | 11 | $31,350 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 114 | $27,202 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 44 | $25,048 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Nucala, Incruse Ellipta | $161,496 | $1,434,2621,983 claims |
| Boehringer IngelheimOfev, Stiolto Respimat, Combivent Respimat, Spiriva Respimat | $12,783 | $819,758221 claims |
| AstraZenecaBreztri Aerosphere, Symbicort, Bevespi Aerosphere | $2,497 | $154,182242 claims |
| PfizerEliquis, Abrysvo | $258 | $100,51694 claims |
| Johnson & JohnsonXarelto | $489 | $57,33653 claims |
| United Therapeutics CorporationAdcirca | $521 | $45,87011 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 295 pulmonary disease providers in Missouri.
Other pulmonary disease in Chesterfield
- Neil EttingerChesterfield$71K
- Kristen FisherChesterfield$15K
- Humam FarahHannibal$840K
- Derek ByersSaint Louis$835K
- Alexander ChenSaint Louis$679K
- Joseph OjileSaint Louis$538K
- Munaf SiyamwalaIndependence$413K
- Edward CharbekSaint Louis$372K
- Adeel KhanWashington$316K
- Marin KollefSaint Louis$264K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.